Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[4-(benzyloxy)phenyl]glycinamide
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
N-[4-(benzyloxy)phenyl]glycinamide is a synthetic small molecule belonging to the class of alpha amino acid amides. It acts as an inhibitor of leukotriene A-4 hydrolase, an enzyme involved in the biosynthesis of leukotriene B4, which plays a role in inflammation. The compound has been studied experimentally but is not approved for clinical use and has no known marketed indications[3][2][1]. Its primary mechanism is inhibition of leukotriene A-4 hydrolase.
- Other names
- 2-amino-N-(4-(benzyloxy)phenyl)acetamide2-amino-N-[4-(benzyloxy)phenyl]acetamideN-[4-(Benzyloxy)phényl]glycinamideAcetamide, 2-amino-N-[4-(phenylmethoxy)phenyl]
02
Targets
LTA4H (Leukotriene A4 hydrolase)
Beyond the preview
Go deeper on N-[4-(benzyloxy)phenyl]glycinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[4-(benzyloxy)phenyl]glycinamide.